Myriad Genetics, Inc. (MYGN): Price and Financial Metrics

Myriad Genetics, Inc. (MYGN): $19.26

-1.11 (-5.45%)

POWR Rating

Component Grades














  • MYGN scores best on the Growth dimension, with a Growth rank ahead of 83.26% of US stocks.
  • The strongest trend for MYGN is in Growth, which has been heading up over the past 177 days.
  • MYGN ranks lowest in Momentum; there it ranks in the 1st percentile.

MYGN Stock Summary

  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.32 for MYRIAD GENETICS INC; that's greater than it is for merely 19.12% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, MYRIAD GENETICS INC is reporting a growth rate of 134.91%; that's higher than 89.11% of US stocks.
  • Revenue growth over the past 12 months for MYRIAD GENETICS INC comes in at -3.36%, a number that bests just 20.07% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to MYRIAD GENETICS INC, a group of peers worth examining would be ANGO, LIQT, LPTH, ITI, and NRDS.
  • MYGN's SEC filings can be seen here. And to visit MYRIAD GENETICS INC's official web site, go to

MYGN Valuation Summary

  • In comparison to the median Healthcare stock, MYGN's EV/EBIT ratio is 231.31% lower, now standing at -13.
  • MYGN's price/sales ratio has moved down 3 over the prior 243 months.

Below are key valuation metrics over time for MYGN.

Stock Date P/S P/B P/E EV/EBIT
MYGN 2023-01-20 2.5 1.8 -21.3 -13.0
MYGN 2023-01-19 2.4 1.7 -20.5 -12.4
MYGN 2023-01-18 2.4 1.7 -20.6 -12.5
MYGN 2023-01-17 2.3 1.6 -19.5 -11.8
MYGN 2023-01-13 2.3 1.7 -19.6 -11.9
MYGN 2023-01-12 2.3 1.7 -19.7 -12.0

MYGN Growth Metrics

    Its 3 year revenue growth rate is now at -17.84%.
  • The 3 year net income to common stockholders growth rate now stands at -153.59%.
  • Its 2 year net income to common stockholders growth rate is now at 94.47%.
MYGN's revenue has moved down $152,000,000 over the prior 33 months.

The table below shows MYGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 661.4 -108.5 -77.3
2022-06-30 672.3 -146 -17.6
2022-03-31 682.4 -100.1 -8.2
2021-12-31 690.6 18.2 -27.2
2021-09-30 684.4 13.7 -57.5
2021-06-30 662.3 -6.3 -97.3

MYGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MYGN has a Quality Grade of C, ranking ahead of 61.95% of graded US stocks.
  • MYGN's asset turnover comes in at 0.476 -- ranking 93rd of 681 Pharmaceutical Products stocks.
  • CDXC, CEMI, and GERN are the stocks whose asset turnover ratios are most correlated with MYGN.

The table below shows MYGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.476 0.705 -0.277
2021-03-31 0.404 0.685 -0.395
2020-12-31 0.390 0.680 -0.514
2020-09-30 0.407 0.698 -0.425
2020-06-30 0.424 0.709 -0.380
2020-03-31 0.493 0.737 -0.285

MYGN Price Target

For more insight on analysts targets of MYGN, see our MYGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.25 Average Broker Recommendation 2.11 (Hold)

MYGN Stock Price Chart Interactive Chart >

Price chart for MYGN

MYGN Price/Volume Stats

Current price $19.26 52-week high $28.18
Prev. close $20.37 52-week low $13.92
Day low $19.15 Volume 433,900
Day high $20.01 Avg. volume 584,542
50-day MA $18.27 Dividend yield N/A
200-day MA $20.45 Market Cap 1.56B

Myriad Genetics, Inc. (MYGN) Company Bio

Myriad Genetics discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties to improve patient care. The company was founded in 1991 and is based in Salt Lake City, Utah.

MYGN Latest News Stream

Event/Time News Detail
Loading, please wait...

MYGN Latest Social Stream

Loading social stream, please wait...

View Full MYGN Social Stream

Latest MYGN News From Around the Web

Below are the latest news stories about MYRIAD GENETICS INC that investors may wish to consider to help them evaluate MYGN as an investment opportunity.

3 Gene Editing Stocks With the Best Long-Term Potential

These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space

Muslim Farooque on InvestorPlace | January 25, 2023

Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock

Raymond James upgraded Natera Inc (NASDAQ: NTRA) to Outperform from Market Perform and a price target of $58 on a catalyst-rich setup for 2023 across segments, but most interestingly, in the molecular residual disease arena. The analyst expects additional coverage and potential guideline inclusion, at least for colorectal cancer, with women's health having its catalysts. The analyst also upgraded Myriad Genetics Inc (NASDAQ: MYGN) to Outperform from Market Perform and a price target of $25. Raym

Yahoo | January 18, 2023

Myriad Genetics (MYGN) Ailed by Mounting Costs, FX Headwind

Myriad Genetics' (MYGN) significant gross margin contraction and operating loss as a result of mounting cost pressure are concerning.

Yahoo | January 10, 2023

Was anything positive for Myriad Genetics Inc. (MYGN) stock last session?

Myriad Genetics Inc. (NASDAQ:MYGN) closed Thursday at $16.03 per share, up from $16.01 a day earlier. While Myriad Genetics Inc. has overperformed by 0.12%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MYGN fell by -39.99%, with highs and lows ranging from $28.18 to $13.92, whereas […]

US Post News | January 6, 2023

Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities

SALT LAKE CITY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for a recent guideline update by the American College of Medical Genetics and Genomics (ACMG), reaffirming the clinical value of non-invasive prenatal screening (NIPS) for a range of chromosomal abnormalities. Myriad is dedicated to advancing NIPS with best-in-class technology and important product launches.

GlobeNewswire | January 5, 2023

Read More 'MYGN' Stories Here

MYGN Price Returns

1-mo 32.74%
3-mo 18.16%
6-mo -29.71%
1-year -26.74%
3-year -30.34%
5-year -48.84%
YTD 32.74%
2022 -47.43%
2021 39.57%
2020 -27.38%
2019 -6.33%
2018 -15.36%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7013 seconds.